Recent Updates
Recently added Catalysts

palifosfamide-tris

Phase 3

Advanced Solid Tumors | Small Molecules | Oncology |Alaunos Therapeutics, Inc.|Trials Updated: Sep 29, 2026

palifosfamide-tris development status

Highest phase Phase 3 (NCT01168791)
Phase scored for TCRTPhase 1
Registered trials 5 across 1 sponsor since Jul 2008

palifosfamide-tris target and mechanism

ModalitySmall Molecules

Also known as isophosphoramide mustard-tris, Zymafos (TM)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials2
Total Enrollment46

FDA Designations

No designations recorded

palifosfamide-tris clinical trials

palifosfamide-tris · 2 trials · 9 indications

Phase 1 2
NCT01340547Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid TumorsAdvanced Solid Tumors
COMPLETED24 Analytics
NCT01242072Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With MalignanciesMalignancy
COMPLETED22 Analytics
PHASE1COMPLETED
Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors
Advanced Solid TumorsUnlock trial analytics
PHASE1COMPLETED
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
MalignancyUnlock trial analytics

Study Endpoints

Primary Endpoints

ECG QTc intervals of patients who receive palifosfamide-tris
Cycle 1 Days -1,1, 2, 3,8

To assess the effect of single-agent palifosfamide-tris on QTc intervals.

Blood sampling to characterize the pharmacokinetics of palifosfamide-tris
Cycle 1, Day 1, 2, 3, 4, 8

To assess the pharmacokinetic profile of single-agent palifosfamide-tris.

Assess the safety profile
21 Days

Adverse events, vital signs, physical examination, laboratory data and concomitant medications

Secondary Endpoints

Safety and tolerability of palifosfamide-tris measured in amount, type, severity and relatedness of Adverse Events
Duration of time patient is on study, expected average of 5 months
Preliminary efficacy of palifosfamide-tris as it pertains to cancer tumor growth
Duration of time patient is on study, expected average of 5 months
Determine the maximum tolerated dose
Up to 21 days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single ArmOTHERSingle Arm, non-blinded, non-randomized
PaCEEXPERIMENTALPalifosfamide, Carboplatin and Etoposide

Interventions

NameTypeDescription
palifosfamide-trisDRUGpalifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
Normal SalineDRUG0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion criteria: 1. Male or female subjects, age ≥ 18 years, who have provided written informed consent prior to completing any study specific procedure. 2. Histologically or cytologically confirmed solid tumor that has progressed following available standard therapies or for which no standard t...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Advanced Solid Tumors")

Recent Changes (Last 90 Days)

MEDIUMOct 30, 2026NCT01242072TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT01340547TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT01242072TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT01340547TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT01340547TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT01242072TRIAL_REMOVED: changed

Frequently asked questions about palifosfamide-tris

What is palifosfamide-tris?

Palifosfamide-tris is an investigational small molecule oncology drug being developed by Alaunos Therapeutics, Inc. It has been studied in Phase 1 clinical trials in patients with advanced solid tumors and other malignancies. It is not an approved therapy and remains in clinical development.

What is palifosfamide-tris used for?

Palifosfamide-tris has been studied in patients with advanced solid tumors and malignancies, including non small cell lung cancer, small cell lung cancer, testicular cancer, thymoma, ovarian cancer, and osteosarcoma. All of this testing has been in Phase 1 trials, so the drug is investigational and has no approved indication.

Who is developing palifosfamide-tris?

Palifosfamide-tris is being developed by Alaunos Therapeutics, Inc., which trades under the ticker TCRT. The company has sponsored Phase 1 studies of the small molecule in advanced solid tumors and in combination with chemotherapy in patients with various malignancies.

What phase is palifosfamide-tris in?

Palifosfamide-tris is in Phase 1 clinical development. Its trials in advanced solid tumors and malignancies have been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.

What clinical trials has palifosfamide-tris been studied in?

Palifosfamide-tris has been evaluated in two completed Phase 1 trials. NCT01340547 studied single-agent palifosfamide-tris for its effect on QTc, pharmacokinetics, safety, and preliminary efficacy in 24 patients with advanced solid tumors. NCT01242072 studied intravenous palifosfamide-tris with etoposide and carboplatin in 22 patients with malignancies.